Eversense XL - up to 180 days of Freedom

Say hello to the Eversense XL Continuous Glucose Monitoring (CGM) System,
A new alternative to traditional CGM.

Learn More About Eversense XL CGM System
The Eversense Sensor is no longer contraindicated for use with some MRI Scans! Click here to learn more.

Eversense XL CGM System

Eversense Sensor

Up to 180-Days of Sensor Life

Other CGM systems require a sensor removal and reinsertion every 2 weeks or more, while the Eversense XL Sensor lasts up to 180 days.

Smart Transmitter

Smart Transmitter

Eversense XL offers you the flexibility and discretion to remove the transmitter without wasting a sensor. 

Eversense App

iOS and Android App

With Eversense XL, you can see your readings directly on your compatible mobile device. And with readings every 5 minutes, you can see where you are now and where you’re headed with the trend arrows.3

What is Long-Term CGM?

Eversense XL CGM System

Eversense XL is the first and only long-term CGM that has a sensor that lasts up to 180 days and is changed by your health care provider - no more weekly self-insertions. Eversense provides you with the freedom you've always wanted in a CGM.

  • 288 readings every 24 hours
    Glucose readings and trend arrows every 5 minutes help show not only where you are, but where you're going, and can help you manage your diabetes before going too high or too low.

    Gentle, non-irritating adhesive
    Eversense uses a gentle silicone-based adhesive that’s gentle on the skin.

    Alerts you can see, feel and hear
    Eversense XL can send you pop-up messages on your phone, sound an alert or vibrate on your arm to alert you to highs and lows, based on your customized settings.

    No Sensor Self-Insertion
    Eversense XL is inserted by your health care provider and lasts up to 180 days, letting you avoid the burdensome self-insertion process every 7-14 days.




1 Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68. 
2 Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D., ... & Kelley, L. (2018). A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. (PRECISE II).7. Glycemic Targets: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018;41(Suppl. 1):S55–S64 
3 Data on file.

MKT-1101 Rev 3

Important Update: August 10, 2020

Senseonics announces agreement to collaborate with Ascensia Diabetes Care

On August 10, 2020 we announced the formation of a collaboration and commercialization agreement between Senseonics, Incorporated and Ascensia Diabetes Care, maker of the CONTOUR® portfolio of blood glucose monitoring systems.

This new agreement begins in 2021 and at the present time does not lead to any changes in how you obtain Eversense XL CGM, how you schedule your insertions and removals, or who you contact if you have any issues. Please continue to use the same contacts you are using now for your needs concerning Eversense XL and for Customer Care.

More information will be coming in the future.


Francine Kaufman, MD and the Senseonics Leadership Team

To read the press release, click press release. To learn more about Ascensia Diabetes Care, click Ascensia Diabetes Care.